Pharma Focus Asia
Klöckner Pentaplast - Pentapharm® alfoil® films

Telisotuzumab Vedotin (Teliso-V) Developed for the Treatment of Non-Small Cell Lung Cancer

AbbVie developed Telisotuzumab Vedotin (Teliso-V) an investigational antibody-drug conjugate (ADC), to treat patients with non-small cell lung cancer (NSCLC).

(Teliso-V) is used to treat patients with advanced/metastatic epidermal growth factor receptor (EGFR) wild type, nonsquamous non-small cell lung cancer (NSCLC) consisting of high levels of c-Met overexpression whose disease has advanced on or after platinum-based therapy.

Patients undergoing standard of care therapies, including prior platinum have limited treatment options and poor prognosis.

Currently there are no approved cancer therapies specifically for patients with c-Met overexpressing NSCLC. Teliso-V i in combination with osimertinib is being evaluated in the ongoing Phase 1 study M14-237 in patients with previously treated c-Met overexpressing NSCLC.

U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy Designation (BTD) to investigational telisotuzumab vedotin (Teliso-V) for previously treated non-small cell lung cancer.

In U.S and worldwide, although having advanced treatments options lung cancer remains the most common type of cancer among both men and women. Moreover, it is the third most common cancer in females and affecting males. Approximately 85% of lung cancers are classified as NSCLC.

magazine-slider-imageBIOVIA from Molecule to MedicineMFA + MMA 2024CPHI China || PMEC China 2024Asia Healthcare Week 2024Advance DoE WorkshopCPHI Korea 2024CHEMICAL INDONESIA 2024INALAB 2024 Thermo Scientific - DynaDrive and DynaSpinRehab Expo 2024ISPE Singapore Affiliate Conference & Exhibition 20242024 PDA Cell and Gene Pharmaceutical Products Conference 2024 PDA Aseptic Manufacturing Excellence Conference2024 PDA Aseptic Processing of Biopharmaceuticals Conference3rd World ADC Asia 2024LogiPharma Asia 2024